What is the rationale for novel combination therapies?
Niels van de Donk
The issue of drug cost: transparent pricing & acceptable profit margins
How can standard risk multiple myeloma (MM) patients be cured?
An update on two trials evaluating venetoclax in subsets of CLL
Venetoclax in combination with ibrutinib: can it control CLL?